- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00117845
Phase II Study of the Efficacy and Toxicity of Ontak(Registered Trademark) (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia
Phase II Study of the Efficacy and Toxicity of Ontak (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia
Adult T-cell leukemia (ATL) is and aggressive characterized by the presence of cluster of differentiation 4 (CD4)/cluster of differentiation 25 (CD25)-expressing T cells (interleukin-2 [IL-2]R expressing) in the peripheral blood and in lymphoid and other tissues. Denileukin diftitox (Ontak(Registered Trademark)) is a genetically engineered fusion protein that targets IL-2-expressing malignancies. Denileukin diftitox interacts with the IL-2R on the cell surface, is internalized via endocytosis, and inhibits cellular protein synthesis, resulting in cell death within hours to days. The objectives of this study are to determine the clinical response to Denileukin diftitox of patients with adult T-cell leukemia (ATL) and the safety of Denileukin diftitox in those patients.
Eligible participants must be 18 years of age or older with chronic, lymphomatous and acute forms of ATL, and must be infected with human T-cell lymphotropic virus type I (HTLV1).
Patients will be treated with 9 mcg/kg/d of Denileukin diftitox intravenously for 5 days every 2 weeks. Tumor response will be evaluated after two cycles of treatment. Stable or responding patients will continue treatment for a total of 12 months, with evaluations every four cycles of treatment. Patients will be treated for two cycles beyond a complete remission. The trial uses an optimal two-stage design targeting for a true response proportion of more than 30 percent. Nine patients will be treated initially, with expansion to 29 patients if a response is seen in 1 of the initial 9 patients treated. Treatment will be discontinued if a patient experiences serious side effects.
A potential benefit is that a patient may undergo partial or complete remission. The research may not directly benefit participants, but the results may aid in the treatment of others.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background:
Adult T-Cell Leukemia is a lymphoproliferative disorder characterized by the presence of CD4/CD25 expressing T cells (IL-2R expressing) in the peripheral blood, in lymphoid and other tissues.
Denileukin diftitox is a genetically engineered fusion protein combining the enzymatically active domains of diphtheria toxin (DT) and the full length sequence of interleukin-2 (IL-2) that targets IL-2 expressing malignancies.
Denileukin diftitox interacts with the IL-2 R on the cell surface, is internalized via endocytosis, and inhibits cellular protein synthesis resulting in cell death within hours to days.
Objective:
Determine the clinical response to Denileukin diftitox (Ontak) of patients with adult T-cell leukemia (ATL).
Define the safety of Denileukin diftitox in patients who have ATL.
Eligibility:
Patients with chronic, lymphomatous and acute forms of ATL.
Patients must be human T-cell lymphotropic virus type I (HTLV1) positive.
Design:
Patients will be treated with 9mcg/kg/d of Denileukin diftitox for five days, on an every two week schedule.
Tumor response will be evaluated after two cycles of treatment. Stable or responding patients will continue treatment with evaluations every four cycles of treatment. Patients will be treated for two cycles beyond a complete remission.
The trial uses an optimal 2 stage design targeting for a true response proportion greater than 30%. Nine patients will be treated initially with expansion to 29 patients if a response is seen in one of the initial nine patients treated. If no response is seen at the 9 mcg/kg/d dose an additional 9 patients will be treated at a dose of 18 mcg/kg/d with expansion to 29 patients at this dose level if a response is seen. A stopping rule for excessive toxicity will be incorporated.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- National Institutes of Health Clinical Center, 9000 Rockville Pike
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
- INCLUSION CRITERIA:
Patients must have serum antibodies directed to human T-lymphotropic virus type 1 (HTLV-I).
All patients must have a histologically confirmed diagnosis of adult T-cell leukemia/lymphoma and more than 10% of the malignant cells must express cluster of differentiation 25 (CD25).
All stages of Tac-expressing adult T cell leukemia except smoldering are eligible: patients with chronic, lymphomatous or acute adult T-cell leukemia (ATL) are eligible. (See appendix 2 for characteristics of patients with the various stages of ATL)
Patients must have measurable disease. All patients with greater than 10% abnormal (i.e. TAC homogenous strongly expressing) peripheral blood mononuclear cells (PBMC) in the peripheral blood will be deemed to have measurable disease.
The patient must have a granulocyte count of at least 1000/mm^3 and a platelet count of greater than or equal to 50,000/mm^3.
Patients must have a creatinine of less than 2.0 mg/dl.
Omission of cytotoxic chemotherapy for ATL for 3 weeks prior to entry into the trial is required. However, patients receiving corticosteroids will be eligible.
Patients must have a life expectancy of greater than 2 months.
Eligible patients must be greater than or equal to 18 years old. There is no upper age limit.
Patients must have serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) value less than or equal to 2.5 times the upper limit of normal and bilirubin less than or equal to 3.0/dl. If a liver function test is judged to be elevated due to the underlying ATL, this parameter will be considered an unevaluable parameter for toxicity determinations.
Patients must have a serum albumin greater than or equal to 2.5 g/dl
Patients must be able to understand and sign an Informed Consent form.
All patients must use adequate contraception during participation in this trial and for three months after completing therapy.
EXCLUSION CRITERIA:
Patients with symptomatic leukemic meningitis will be excluded. However, patients that have both ATL and another HTLV-I-associated disease, tropical spastic paraparesis (TSP), will be included.
Pregnant and nursing patients are not eligible for the study.
Human immunodeficiency virus (HIV) positive patients are excluded from the study. Denileukin diftitox may produce a different pattern of toxicities in immunocompromised individuals.
Patients with Smoldering ATL are excluded.
Patients with serious intercurrent illnesses, past history of a myocardial infarction within 6 months or severe coronary artery disease
Patients who previously received Denileukin diftitox are ineligible.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Denileukin Diftitox in ATL
Denileukin Diftitox in adult T-cell leukemia (ATL) Patients will be treated with Denileukin Diftitox 9 mcg/kg/d intravenously for 5 days every 2 weeks.
|
Patients will be treated with Denileukin Diftitox 9 mcg/kg/d intravenously for 5 days every 2 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response Rate
Time Frame: up to 12 months
|
Response rate is based on the number of patients who achieve either a complete response (CR) or partial response (PR) to therapy.
Complete response is complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease related symptoms if present before therapy and normalization of those biochemical abnormalities (for example LDH) definitely assignable to the lymphoma.
Partial response is reduction by >=50% of leukemia cell count or >=50% reduction is the size of all measurable lesions, and no increase in size of any measurable or evaluable lesion or appearance of new lesion.
|
up to 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Serious and Non-Serious Adverse Events
Time Frame: Date treatment consent signed to date off study, approximately 72 months
|
Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v3.0).
A non-serious adverse event is any untoward medical occurrence.
A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.
|
Date treatment consent signed to date off study, approximately 72 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Yates AD, Morgan WT, Watkins WM. Linkage-specific alpha-D-galactosidases from Trichomonas foetus: characterisation of the blood-group B-destroying enzyme as a 1, 3-alpha-galactosidase and the blood-group P1-destroying enzyme as a 1, 4-alpha-galactosidase. FEBS Lett. 1975 Dec 15;60(2):281-5. doi: 10.1016/0014-5793(75)80731-9. No abstract available.
- Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood. 1977 Sep;50(3):481-92. No abstract available.
- Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9. doi: 10.1073/pnas.77.12.7415.
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 050185
- 05-C-0185
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Leukemia, Adult T-Cell
-
UNC Lineberger Comprehensive Cancer CenterSeagen Inc.Active, not recruitingLymphoma | Lymphatic Diseases | Adult T-Cell Leukemia/LymphomaUnited States
-
Columbia UniversityCelgene CorporationCompleted
-
National Cancer Institute (NCI)CompletedAcute Adult T-Cell Leukemia/Lymphoma | Adult T-Cell Leukemia/Lymphoma | Chronic Adult T-Cell Leukemia/Lymphoma | HTLV-1 Infection | Lymphomatous Adult T-Cell Leukemia/Lymphoma | Smoldering Adult T-Cell Leukemia/LymphomaUnited States
-
National Cancer Institute (NCI)TerminatedLeukemia, Adult T-Cell | T Cell Leukemia, Adult | T Cell Leukemia, HTLV I AssociatedUnited States
-
Amit VermaTerminatedAdult T Cell Leukemia | Adult T Cell LymphomaUnited States
-
National Cancer Institute (NCI)CompletedAdult T-Cell Leukemia (ATL)United States
-
Kyowa Kirin Co., Ltd.CompletedAdult T-Cell Leukemia and Lymphoma (ATL) | Adult Peripheral T-Cell Lymphoma (PTCL)Japan
-
Daiichi Sankyo Co., Ltd.Active, not recruitingAdult T-cell Leukemia/LymphomaJapan
-
Kyowa Kirin, Inc.CompletedAdult T-cell Leukemia-LymphomaUnited States, United Kingdom, Belgium, France, Brazil, Peru
-
National Cancer Institute (NCI)CompletedPeripheral T-Cell Lymphoma (PTCL) | T-Cell Prolymphocytic Leukemia | Cutaneous T Cell Lymphoma (CTCL) | T-Cell Lymphoma Relapsed | Adult T-Cell Leukemia (ATL)United States
Clinical Trials on Denileukin diftitox (Ontak)
-
Barbara Ann Karmanos Cancer InstituteEisai Inc.TerminatedMultiple MyelomaUnited States
-
Eisai Inc.No longer available
-
Eisai Inc.CompletedLymphoma, B-CellUnited States
-
The University of Texas Health Science Center at...CompletedEpithelial Ovarian Cancer | Fallopian Tube Carcinoma | Extraovarian Peritoneal CancerUnited States
-
James Graham Brown Cancer CenterUniversity of LouisvilleCompleted
-
Loyola UniversityEisai Inc.; Riveria Country Club OrganizationTerminatedMetastatic Pancreatic CancerUnited States
-
M.D. Anderson Cancer CenterCompletedLeukemia | Systemic MastocytosisUnited States
-
Eisai Inc.National Cancer Institute (NCI); Tufts Medical Center; Ligand PharmaceuticalsCompleted
-
The University of Texas Health Science Center at...TerminatedEpithelial Ovarian Cancer | Fallopian Tube Carcinoma | Extraovarian Peritoneal CancerUnited States
-
Eastern Cooperative Oncology GroupNational Cancer Institute (NCI)Completed